Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases

Giovanni Scambia; Angelo Di Giorgio; Pierandrea De Iaco; Michele De Simone; Alfredo Garofalo; Antonio Daniele Pinna; Giorgio Maria Verdecchia; Luca Ansaloni; Antonio Macrì; Paolo Cappellini; Valerio Ceriani; Giorgio Giorda; Daniele Biacchi; Marco Vaira; Mario Valle; Paolo Sammartino

doi:10.1245/s10434-016-5686-1

Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases

Giovanni Scambia, Angelo Di Giorgio, Pierandrea De Iaco, Michele De Simone, Alfredo Garofalo, Antonio Daniele Pinna, Giorgio Maria Verdecchia, Luca Ansaloni, Antonio Macrì, Paolo Cappellini, Valerio Ceriani, Giorgio Giorda, Daniele Biacchi, Marco Vaira, Mario Valle, Paolo Sammartino

Risultato della ricerca: Contributo in rivista › Articolo in rivista

48 Citazioni (Scopus)

Abstract

Purpose: The aim of this study was to help with the process of selecting patients with advanced ovarian cancer to undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) by analyzing outcome data at distinct clinical time points reflecting the natural history of the disease. Methods: In a retrospective Italian multicenter study investigating patients with advanced ovarian cancer who underwent CRS plus HIPEC between 1998 and 2014, we analyzed data for consecutive patients at eight treatment time points: primary debulking surgery (PDS); interval debulking surgery after partial response, after no response, and after a pathologic complete response to neoadjuvant chemotherapy; first recurrence with a progression-free interval >12, <12Â months, or >12Â months in patients who underwent further chemotherapy before CRS and HIPEC; and patients who underwent two or more CRS procedures and chemotherapy lines before CRS and HIPEC. Results: The 511 enrolled patients underwent 3373 procedures; 72.6% achieved complete cytoreduction, with an overall major morbidity of 17.4%. At a median follow-up of 53.8Â months, overall survival (OS) was 54.2 months (95% confidence interval [CI] 44â58.4) and progression-free (PFS) survival was 16.6Â months (95% CI 14.7â19.1). Outcome analysis in patients in whom CRS plus HIPEC was used for primary advanced cancer or recurrent ovarian cancer showed significant differences in OS and PFS according to the timeÂ points analyzed. Multivariate analysis identified completeness of CRS, Peritoneal Cancer Index, and the times when patients underwent CRS plus HIPEC as independent prognostic factors. Conclusions: This selective information on survival should help in interpreting the findings from ongoing randomized studies focusing on CRS plus HIPEC in patients with advanced ovarian cancer.

Lingua originale	English
pagine (da-a)	914-922
Numero di pagine	9
Rivista	Annals of Surgical Oncology
Volume	24
DOI	https://doi.org/10.1245/s10434-016-5686-1
Stato di pubblicazione	Pubblicato - 2017

Keywords

Oncology
Surgery

Accesso al documento

10.1245/s10434-016-5686-1

Altri file e collegamenti

Fingerprint Entra nei temi di ricerca di 'Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases'. Insieme formano una fingerprint unica.

Cita questo

Scambia, G., Di Giorgio, A., De Iaco, P., De Simone, M., Garofalo, A., Pinna, A. D., Verdecchia, G. M., Ansaloni, L., Macrì, A., Cappellini, P., Ceriani, V., Giorda, G., Biacchi, D., Vaira, M., Valle, M., & Sammartino, P. (2017). Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. Annals of Surgical Oncology, 24, 914-922. https://doi.org/10.1245/s10434-016-5686-1

Scambia, Giovanni ; Di Giorgio, Angelo ; De Iaco, Pierandrea ; De Simone, Michele ; Garofalo, Alfredo ; Pinna, Antonio Daniele ; Verdecchia, Giorgio Maria ; Ansaloni, Luca ; Macrì, Antonio ; Cappellini, Paolo ; Ceriani, Valerio ; Giorda, Giorgio ; Biacchi, Daniele ; Vaira, Marco ; Valle, Mario ; Sammartino, Paolo. / Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. In: Annals of Surgical Oncology. 2017 ; Vol. 24. pagg. 914-922.

@article{ee476a8fbab84051bd2465299d9612c0,

title = "Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases",

abstract = "Purpose: The aim of this study was to help with the process of selecting patients with advanced ovarian cancer to undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) by analyzing outcome data at distinct clinical time points reflecting the natural history of the disease. Methods: In a retrospective Italian multicenter study investigating patients with advanced ovarian cancer who underwent CRS plus HIPEC between 1998 and 2014, we analyzed data for consecutive patients at eight treatment time points: primary debulking surgery (PDS); interval debulking surgery after partial response, after no response, and after a pathologic complete response to neoadjuvant chemotherapy; first recurrence with a progression-free interval >12, <12{\^A} months, or >12{\^A} months in patients who underwent further chemotherapy before CRS and HIPEC; and patients who underwent two or more CRS procedures and chemotherapy lines before CRS and HIPEC. Results: The 511 enrolled patients underwent 3373 procedures; 72.6% achieved complete cytoreduction, with an overall major morbidity of 17.4%. At a median follow-up of 53.8{\^A} months, overall survival (OS) was 54.2 months (95% confidence interval [CI] 44{\^a}58.4) and progression-free (PFS) survival was 16.6{\^A} months (95% CI 14.7{\^a}19.1). Outcome analysis in patients in whom CRS plus HIPEC was used for primary advanced cancer or recurrent ovarian cancer showed significant differences in OS and PFS according to the time{\^A} points analyzed. Multivariate analysis identified completeness of CRS, Peritoneal Cancer Index, and the times when patients underwent CRS plus HIPEC as independent prognostic factors. Conclusions: This selective information on survival should help in interpreting the findings from ongoing randomized studies focusing on CRS plus HIPEC in patients with advanced ovarian cancer.",

keywords = "Oncology, Surgery, Oncology, Surgery",

author = "Giovanni Scambia and {Di Giorgio}, Angelo and {De Iaco}, Pierandrea and {De Simone}, Michele and Alfredo Garofalo and Pinna, {Antonio Daniele} and Verdecchia, {Giorgio Maria} and Luca Ansaloni and Antonio Macr{\`i} and Paolo Cappellini and Valerio Ceriani and Giorgio Giorda and Daniele Biacchi and Marco Vaira and Mario Valle and Paolo Sammartino",

year = "2017",

doi = "10.1245/s10434-016-5686-1",

language = "English",

volume = "24",

pages = "914--922",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

publisher = "SPRINGER, 233 SPRING STREET, NEW YORK, USA, NY, 10013",

}

Scambia, G, Di Giorgio, A, De Iaco, P, De Simone, M, Garofalo, A, Pinna, AD, Verdecchia, GM, Ansaloni, L, Macrì, A, Cappellini, P, Ceriani, V, Giorda, G, Biacchi, D, Vaira, M, Valle, M & Sammartino, P 2017, 'Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases', Annals of Surgical Oncology, vol. 24, pagg. 914-922. https://doi.org/10.1245/s10434-016-5686-1

Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. / Scambia, Giovanni; Di Giorgio, Angelo; De Iaco, Pierandrea; De Simone, Michele; Garofalo, Alfredo; Pinna, Antonio Daniele; Verdecchia, Giorgio Maria; Ansaloni, Luca; Macrì, Antonio; Cappellini, Paolo; Ceriani, Valerio; Giorda, Giorgio; Biacchi, Daniele; Vaira, Marco; Valle, Mario; Sammartino, Paolo.

In: Annals of Surgical Oncology, Vol. 24, 2017, pag. 914-922.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases

AU - Scambia, Giovanni

AU - Di Giorgio, Angelo

AU - De Iaco, Pierandrea

AU - De Simone, Michele

AU - Garofalo, Alfredo

AU - Pinna, Antonio Daniele

AU - Verdecchia, Giorgio Maria

AU - Ansaloni, Luca

AU - Macrì, Antonio

AU - Cappellini, Paolo

AU - Ceriani, Valerio

AU - Giorda, Giorgio

AU - Biacchi, Daniele

AU - Vaira, Marco

AU - Valle, Mario

AU - Sammartino, Paolo

PY - 2017

Y1 - 2017

N2 - Purpose: The aim of this study was to help with the process of selecting patients with advanced ovarian cancer to undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) by analyzing outcome data at distinct clinical time points reflecting the natural history of the disease. Methods: In a retrospective Italian multicenter study investigating patients with advanced ovarian cancer who underwent CRS plus HIPEC between 1998 and 2014, we analyzed data for consecutive patients at eight treatment time points: primary debulking surgery (PDS); interval debulking surgery after partial response, after no response, and after a pathologic complete response to neoadjuvant chemotherapy; first recurrence with a progression-free interval >12, <12Â months, or >12Â months in patients who underwent further chemotherapy before CRS and HIPEC; and patients who underwent two or more CRS procedures and chemotherapy lines before CRS and HIPEC. Results: The 511 enrolled patients underwent 3373 procedures; 72.6% achieved complete cytoreduction, with an overall major morbidity of 17.4%. At a median follow-up of 53.8Â months, overall survival (OS) was 54.2 months (95% confidence interval [CI] 44â58.4) and progression-free (PFS) survival was 16.6Â months (95% CI 14.7â19.1). Outcome analysis in patients in whom CRS plus HIPEC was used for primary advanced cancer or recurrent ovarian cancer showed significant differences in OS and PFS according to the timeÂ points analyzed. Multivariate analysis identified completeness of CRS, Peritoneal Cancer Index, and the times when patients underwent CRS plus HIPEC as independent prognostic factors. Conclusions: This selective information on survival should help in interpreting the findings from ongoing randomized studies focusing on CRS plus HIPEC in patients with advanced ovarian cancer.

AB - Purpose: The aim of this study was to help with the process of selecting patients with advanced ovarian cancer to undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) by analyzing outcome data at distinct clinical time points reflecting the natural history of the disease. Methods: In a retrospective Italian multicenter study investigating patients with advanced ovarian cancer who underwent CRS plus HIPEC between 1998 and 2014, we analyzed data for consecutive patients at eight treatment time points: primary debulking surgery (PDS); interval debulking surgery after partial response, after no response, and after a pathologic complete response to neoadjuvant chemotherapy; first recurrence with a progression-free interval >12, <12Â months, or >12Â months in patients who underwent further chemotherapy before CRS and HIPEC; and patients who underwent two or more CRS procedures and chemotherapy lines before CRS and HIPEC. Results: The 511 enrolled patients underwent 3373 procedures; 72.6% achieved complete cytoreduction, with an overall major morbidity of 17.4%. At a median follow-up of 53.8Â months, overall survival (OS) was 54.2 months (95% confidence interval [CI] 44â58.4) and progression-free (PFS) survival was 16.6Â months (95% CI 14.7â19.1). Outcome analysis in patients in whom CRS plus HIPEC was used for primary advanced cancer or recurrent ovarian cancer showed significant differences in OS and PFS according to the timeÂ points analyzed. Multivariate analysis identified completeness of CRS, Peritoneal Cancer Index, and the times when patients underwent CRS plus HIPEC as independent prognostic factors. Conclusions: This selective information on survival should help in interpreting the findings from ongoing randomized studies focusing on CRS plus HIPEC in patients with advanced ovarian cancer.

KW - Oncology

KW - Surgery

KW - Oncology

KW - Surgery

UR - http://hdl.handle.net/10807/111113

UR - http://www.springerlink.com/

U2 - 10.1245/s10434-016-5686-1

DO - 10.1245/s10434-016-5686-1

M3 - Article

VL - 24

SP - 914

EP - 922

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -